Galectin Therapeutics (GALT) Total Liabilities (2010 - 2026)

Galectin Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $146.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 19.88% year-over-year to $146.0 million in Q1 2026; TTM through Mar 2026 was $146.0 million, a 19.88% increase from a year earlier, with the FY2025 full-year figure at $145.7 million, up 20.87% from the prior year.
• Total Liabilities held at $146.0 million in Q1 2026 per GALT's latest filing, from $145.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $146.0 million in Q1 2026 and bottomed at $39.8 million in Q1 2022.
• The 5-year median for Total Liabilities is $97.0 million (2024), against an average of $94.2 million.
• Across the five-year window, Total Liabilities jumped 753.7% in 2022 and gained 12.34% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $53.5 million in 2022, then surged by 65.38% to $88.4 million in 2023, then jumped by 36.32% to $120.6 million in 2024, then increased by 20.87% to $145.7 million in 2025, then gained by 0.18% to $146.0 million in 2026.
• Per Business Quant, the three latest GALT Total Liabilities figures stand at $146.0 million (Q1 2026), $145.7 million (Q4 2025), and $136.4 million (Q3 2025).